MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

BACKGROUND: Multiple myeloma (MM) patients with t(14;20) have a poor prognosis and their outcome has not improved following the introduction of bortezomib (Bzb). The mechanism underlying the resistance to proteasome inhibitors (PIs) for this subset of patients is unknown. METHODS: IC50 of Bzb and ca...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Qiang, Ya-Wei, Ye, Shiqiao, Huang, Yuhua, Chen, Yu, Van Rhee, Frits, Epstein, Joshua, Walker, Brian A., Morgan, Gareth J., Davies, Faith E.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6035431/
https://ncbi.nlm.nih.gov/pubmed/29980194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4602-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars